Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | NA |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | 131 I | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | thyroid cancer |
| ICD-0-3 | C73.9 |
| Methods | qPCR, Western blot, Dual luciferase reporter assay, RIP |
| Sample | thyroid carcinoma tissues, cell lines (FTC-133 ,TPC-1, 293T) |
| Expression Pattern | down-regulated |
| Function Description | MEG3 expression was down-regulated in TC tumor tissues, and the cumulative survival rate was decreased in low MEG3 expression group in TC patients under 131I treatment. MEG3 expression appeared a decline and miR-182 expression displayed an increase in 131I-resistant FTC-133 (res-FTC-133) and TPC-1 (res-TPC-1) cells. Moreover, MEG3 overexpression suppressed 131I-resistant cell viability, promoted apoptosis and induced DNA damage. |
| Pubmed ID | 30021359 |
| Year | 2018 |
| Title | LncRNA MEG3 Enhances 131 I Sensitivity in Thyroid Carcinoma via Sponging miR-182. |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for thyroid cancer | OMIM COSMIC |